Quick Answer
Context Therapeutics Inc. reported Stockholders Equity of $60.47 million for fiscal year 2025.
Context Therapeutics Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $60.47M | -36.5% |
| 2024 | $95.27M | +702.5% |
| 2023 | $11.87M | -65.8% |
| 2022 | $34.76M | -28.0% |
| 2021 | $48.27M | +385.3% |
| 2020 | -$16.92M | +29.4% |
| 2019 | -$23.96M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $73.17M | -12.7% | -11.4% |
| June 30, 2025 | $82.54M | -18.4% | -9.3% |
| March 31, 2025 | $90.98M | +977.6% | -4.5% |
| December 31, 2024 | $95.27M | +702.5% | +13.6% |
| September 30, 2024 | $83.86M | +356.1% | -17.1% |
| June 30, 2024 | $101.10M | +321.2% | +1097.5% |
| March 31, 2024 | $8.44M | -70.6% | -28.9% |
| December 31, 2023 | $11.87M | -65.8% | -35.4% |
- Context Therapeutics Inc. showed a decrease of -36.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Context Therapeutics Inc.’s stockholders equity has grown by 352.4% (from -$23.96 million to $60.47 million).
- The most recent figure is from Context Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: